Diagnosis, Testing, and Treatment of NTRK Fusion Cancers in 2026
For those of us managing NTRK fusion cancers, the shift from treating a lung or colon tumor to treating a molecular driver has fundamentally changed how we practice oncology. We’ve officially moved past the honeymoon phase of targeted therapy.
Today, the challenge isn’t just finding a treatment; it is keeping that response going while navigating a global healthcare system that isn’t always set up for precision medicine.
If you are looking at a patient’s NGS report and seeing an NTRK1, NTRK2, or NTRK3 fusion, here is how the clinical reality of these cancers looks right now.
The biology of an NTRK gene fusion
We often describe an NTRK gene fusion as a stuck accelerator pedal. The NTRK gene abnormally joins with a partner—like ETV6 or TPM3—and the signaling for cell growth simply never stops.
What is interesting is that the fusion partner matters more than people think. In secretory breast cancer or infantile fibrosarcoma, you’re almost always looking at an ETV6 -NTRK3 fusion.
In lung cancer, it’s usually NTRK1. This distinction is vital because NTRK3 can be notoriously difficult to pick up on standard DNA-based NGS. I’ve seen far too many NTRK fusion cancers go untreated simply because the wrong test was used.
If you suspect a fusion and the DNA report is clean, you absolutely have to run RNA-based sequencing to be sure.
NTRK testing and why the gold standard fails in practice
While the guidelines say NTRK testing via NGS is the gold standard, the practical reality involves a “wait or treat” dilemma. We often see patients with aggressive, metastatic disease where waiting three weeks for an NGS report feels like an eternity.
In these cases, IHC is a fast and cheap screening tool, but it is not perfect. While it catches nearly 100% of NTRK1 and 2 fusions, its sensitivity for NTRK3 drops to around 79%. If you are looking at a suspected Secretory Breast Carcinoma—a cancer where NTRK3 is the usual suspect—a negative IHC result is not enough to rule out NTRK fusion cancers.
Treatment options for NTRK fusion cancers
Choosing between the two primary FDA-approved TRK inhibitors usually comes down to the patient’s comorbidities and whether the cancer has reached the brain.
Larotrectinib efficacy remains the primary workhorse in my practice. The integrated clinical data shows an objective response rate of about 79%, with a high rate of durable responses.
For our pediatric patients, the data is even more encouraging. A 2025 study suggests we might even be able to pause treatment in children who achieve a deep complete response, provided we monitor them like hawks.
In the entrectinib vs larotrectinib debate, I tend to look at entrectinib more if I’m also suspicious of a ROS1 or ALK driver, as it is a bit more promiscuous in its targeting.
Managing the side effects of TRK inhibitors
Patients don’t lose their hair on these drugs, but they do get dizzy. It is a strange, cerebellar dizziness that we don’t see with traditional chemo. Most of my patients describe it as feeling slightly off-balance.
You should also expect a spike in liver enzymes like ALT and AST in the first few weeks of therapy. My rule of thumb is not to panic. Most of these resolve with a short dose interruption. What actually frustrates patients more than the dizziness is the weight gain.
It is a real metabolic side effect of inhibiting the TRK protein, and you need to warn them about it early so they aren’t surprised when the scale starts moving.
What happens when TRK inhibitors stop working
Resistance is the elephant in the room. Most NTRK-positive tumors eventually develop what we call solvent-front mutations, like G595R.
The big news for 2026 is the full data from the TRIDENT-1 trial published in Nature Medicine this past February. We now have Repotrectinib as a validated second-line option.
Even for patients who have progressed on first-generation drugs, we’re seeing response rates around 48% in the pre-treated group. It’s a massive relief to finally have a plan B that actually works for NTRK fusion cancers.
The two-tier oncology reality
I have to be blunt about access. In some regions, getting these drugs is a matter of a signature. In many others, the 30,000 USD per month price tag for brand-name versions is a brick wall.
This is where clinical ethics meets reality. We have had to rely on high-quality generics like Laronib 100 mg to keep our patients on therapy.
When the alternative is no treatment at all, these bioequivalents are more than just an option—they are often the only way to make precision oncology equitable for everyone.
Clinical Takeaways for your Practice
- Prioritize RNA-based NTRK testing because DNA tests miss too many NTRK3 fusions.
- Monitor liver function weekly for the first month to catch early enzyme spikes.
- Prepare for resistance by running a liquid biopsy the moment a patient shows signs of progression to check for new mutations.
Our Research Resource
Nature Medicine (Feb 2026) regarding Repotrectinib in NTRK fusion cancers.
ASCO/JCO (2025) on wait-and-see strategies in pediatric TRK-fusion sarcomas.
NCCN Guidelines (v1.2026) for updated pathways in molecular testing.
This is clinical commentary based on current 2026 data. Always refer to the latest prescribing information and specific patient history before making a final treatment decision.
Frequently Asked Questions (FAQs)
I recommend testing as soon as a patient is diagnosed with metastatic disease, particularly if they are negative for common drivers like EGFR or ALK. It is much better to have this information early rather than waiting until other treatments have failed.
RNA-based NGS is the most reliable method we have. While DNA-based tests are common, they often miss complex fusions in the NTRK3 gene. If the clinical suspicion is high but a DNA test is negative, you should always follow up with an RNA-based panel.
Chemotherapy is an option, but it is rarely as effective. Once a fusion is confirmed, TRK inhibitors are the preferred clinical path because they offer significantly higher response rates and much better quality of life compared to traditional systemic therapy.
The results are impressive, with response rates typically between 70% and 80%. Many of my patients experience durable responses that last for years, though the exact outcome depends on whether the cancer has already developed resistance mutations.
The cancer usually develops a “solvent-front” mutation to bypass the drug. As of 2026, we typically transition these patients to second-generation inhibitors like Repotrectinib. The key is using a liquid biopsy at the first sign of progression to identify the new mutation.
They are rare in common diseases like lung or colon cancer, usually appearing in less than 1% of cases. However, in certain rare pediatric and adult “orphan” tumors, they can be present in over 90% of patients.
The cost is a massive barrier in many regions. Beyond patient assistance programs and clinical trials, we frequently rely on high-quality generic versions like Laronib 100 mg to ensure patients don’t have to stop life-saving therapy.
Patients stay on treatment as long as the drug is working and the side effects are manageable. Many stay on for several years. In rare pediatric cases with a deep response, we are even beginning to explore supervised “treatment holidays.”
